FR2876908A1 - Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis - Google Patents
Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis Download PDFInfo
- Publication number
- FR2876908A1 FR2876908A1 FR0411241A FR0411241A FR2876908A1 FR 2876908 A1 FR2876908 A1 FR 2876908A1 FR 0411241 A FR0411241 A FR 0411241A FR 0411241 A FR0411241 A FR 0411241A FR 2876908 A1 FR2876908 A1 FR 2876908A1
- Authority
- FR
- France
- Prior art keywords
- chaulmoogra
- oil
- treatment
- esters
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000558306 Gynocardia odorata Species 0.000 title claims abstract description 56
- 230000002265 prevention Effects 0.000 title claims abstract description 4
- 230000004130 lipolysis Effects 0.000 title abstract description 4
- 206010007882 Cellulitis Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 208000035484 Cellulite Diseases 0.000 claims abstract description 10
- 206010049752 Peau d'orange Diseases 0.000 claims abstract description 10
- 230000036232 cellulite Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 36
- 150000002148 esters Chemical class 0.000 claims description 11
- SRELFLQJDOTNLJ-UHFFFAOYSA-N hydnocarpic acid Chemical compound OC(=O)CCCCCCCCCCC1CCC=C1 SRELFLQJDOTNLJ-UHFFFAOYSA-N 0.000 claims description 11
- 230000002366 lipolytic effect Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- XADKGDBMULSEAC-UHFFFAOYSA-N 13-cyclopent-2-en-1-yltridec-6-enoic acid Chemical class OC(=O)CCCCC=CCCCCCCC1CCC=C1 XADKGDBMULSEAC-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 150000007513 acids Chemical class 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 159000000001 potassium salts Chemical class 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 abstract description 22
- 102000005962 receptors Human genes 0.000 abstract description 12
- 108020003175 receptors Proteins 0.000 abstract description 12
- 238000009739 binding Methods 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 229940127293 prostanoid Drugs 0.000 abstract description 8
- 150000003814 prostanoids Chemical class 0.000 abstract description 8
- 101710151321 Melanostatin Proteins 0.000 abstract description 6
- 102400000064 Neuropeptide Y Human genes 0.000 abstract description 6
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract description 6
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 abstract description 5
- 102000012301 Neuropeptide Y receptor Human genes 0.000 abstract description 5
- 229960002986 dinoprostone Drugs 0.000 abstract description 5
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 abstract description 4
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 abstract description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract description 4
- 230000001539 anorectic effect Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 241001671327 Hydnocarpus Species 0.000 description 12
- -1 for example Chemical class 0.000 description 11
- 239000000284 extract Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 8
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000004132 lipogenesis Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940008099 dimethicone Drugs 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- SRELFLQJDOTNLJ-HNNXBMFYSA-N (R)-hydnocarpic acid Chemical compound OC(=O)CCCCCCCCCC[C@@H]1CCC=C1 SRELFLQJDOTNLJ-HNNXBMFYSA-N 0.000 description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010024229 Leprosy Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- XMVQWNRDPAAMJB-UHFFFAOYSA-N (+)-13-Cyclopent-2-enyl-tridecansaeure Natural products OC(=O)CCCCCCCCCCCCC1CCC=C1 XMVQWNRDPAAMJB-UHFFFAOYSA-N 0.000 description 2
- XMVQWNRDPAAMJB-QGZVFWFLSA-N (S)-chaulmoogric acid Chemical compound OC(=O)CCCCCCCCCCCC[C@H]1CCC=C1 XMVQWNRDPAAMJB-QGZVFWFLSA-N 0.000 description 2
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- DTHSUAKYTFUSQU-UHFFFAOYSA-N Alepric acid Natural products OC(=O)CCCCCCCCC1CCC=C1 DTHSUAKYTFUSQU-UHFFFAOYSA-N 0.000 description 2
- GMYNCKRSFMEXPG-UHFFFAOYSA-N Aleprylic acid Chemical compound OC(=O)CCCCCCC1CCC=C1 GMYNCKRSFMEXPG-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 244000119461 Garcinia xanthochymus Species 0.000 description 2
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241001598113 Laminaria digitata Species 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000001355 anti-mycobacterial effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002314 glycerols Chemical class 0.000 description 2
- XADKGDBMULSEAC-MMTGSJLXSA-N gorlic acid Chemical compound OC(=O)CCCC\C=C/CCCCCC[C@@H]1CCC=C1 XADKGDBMULSEAC-MMTGSJLXSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940047670 sodium acrylate Drugs 0.000 description 2
- PCZFVTPRFQOIND-RSAXXLAASA-M sodium;11-[(1r)-cyclopent-2-en-1-yl]undecanoate Chemical compound [Na+].[O-]C(=O)CCCCCCCCCC[C@@H]1CCC=C1 PCZFVTPRFQOIND-RSAXXLAASA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- MBGYSHXGENGTBP-UHFFFAOYSA-N 6-(2-ethylhexoxy)-6-oxohexanoic acid Chemical compound CCCCC(CC)COC(=O)CCCCC(O)=O MBGYSHXGENGTBP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000789537 Caloncoba Species 0.000 description 1
- 241001253926 Caloncoba echinata Species 0.000 description 1
- 241001253927 Caloncoba welwitschii Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000870800 Carpotroche Species 0.000 description 1
- 240000005680 Carpotroche brasiliensis Species 0.000 description 1
- 235000017033 Carpotroche brasiliensis Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001179022 Hydnocarpus anthelminthicus Species 0.000 description 1
- 244000242192 Hydnocarpus heterophyllus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940096898 glyceryl palmitate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- YBTLJLASGKDJSG-UHFFFAOYSA-N prop-2-enoyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC(=O)C=C YBTLJLASGKDJSG-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
La présente invention concerne une nouvelle utilisation de l'huile deThe present invention relates to a new use of
chaulmoogra en thérapeutique et en cosmétique, plus particulièrement pour le traitement des surcharges adipeuses et de la cellulite. chaulmoogra in therapeutics and cosmetics, more particularly for the treatment of fat overloads and cellulite.
La peau comprend des couches superficielles, à savoir l'épiderme, et des couches plus profondes, le derme et l'hypoderme, et chacune possède des propriétés spécifiques permettant à l'ensemble de réagir et s'adapter aux conditions de son environnement. L'épiderme, qui est composé de trois types de cellules, à savoir des kératinocytes (90% des cellules épidermiques), des mélanocytes (2 à 3% des cellules épidermiques) et des cellules de Langerhans, constitue la couche externe et joue un rôle fondamental pour assurer la protection et le maintien d'une bonne trophicité. Le derme sert de support à l'épiderme et est principalement constitué de fibroblastes et d'une matrice extracellulaire essentiellement à base de collagène et d'élastine. Les fibres de collagène contribuent à la texture et la tonicité de la peau et l'élastine est responsable de son élasticité. D'autres cellules, comme les macrophages et les leucocytes, sont également présentes dans la couche du derme. L'hypoderme, qui est la couche la plus profonde de la peau, contient les adipocytes qui produisent des lipides pour que le tissu sous-cutané fabrique une couche grasse protégeant les muscles, les os et les organes internes contre les chocs. The skin consists of superficial layers, namely the epidermis, and deeper layers, the dermis and hypodermis, and each has specific properties allowing the whole to react and adapt to the conditions of its environment. The epidermis, which is composed of three types of cells, namely keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells, constitutes the outer layer and plays a role. fundamental to ensure the protection and maintenance of good trophicity. The dermis serves as a support for the epidermis and consists mainly of fibroblasts and an extracellular matrix essentially based on collagen and elastin. Collagen fibers contribute to the texture and tone of the skin and elastin is responsible for its elasticity. Other cells, such as macrophages and leucocytes, are also present in the dermis layer. The hypodermis, which is the deepest layer of skin, contains lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects muscles, bones, and internal organs from shock.
Les adipocytes synthétisent des triglycérides par lipo- génèse à partir d'acides gras libres et de glycérol provenant de la dégradation du glucose. Les acides gras et le glucose sont apportés à l'organisme par les aliments. Inversement, les triglycérides contenus dans les adipocytes subissent une lipolyse sous l'action d'enzymes et libèrent du glycérol ou des esters de glycérol ainsi que des acides gras qui peuvent à leur tour circuler dans l'organisme et/ou être captés par des adipocytes où ils sont à nouveau transformés en triglycérides par lipogénèse. Ainsi, en cas de déséquilibre entre la B1528fr lipogénèse et la lipolyse, il peut se produire une accumulation excessive de triglycérides qui se traduit par des surcharges adipeuses. Adipocytes synthesize triglycerides by lipogenesis from free fatty acids and glycerol from glucose degradation. Fatty acids and glucose are brought to the body by food. Conversely, the triglycerides contained in adipocytes undergo lipolysis by the action of enzymes and release glycerol or glycerol esters as well as fatty acids which can in turn circulate in the body and / or be captured by adipocytes. where they are again transformed into triglycerides by lipogenesis. Thus, in case of imbalance between B1528fr lipogenesis and lipolysis, there can be an excessive accumulation of triglycerides which results in fat overload.
Les surcharges adipeuses sont des défauts susceptibles de nuire à l'aspect esthétique de l'individu, et elles constituent aussi des états physiologiques anormaux chez l'homme, mais surtout chez la femme, où les accumulations de cellulite sont toujours jugées disgracieuses. Ces états pathologiques, bien que différents de l'obésité, nécessitent généralement un traitement systémique. Bien souvent, à défaut de traitement thérapeutique, un traitement cosmétique est souhaité pour lutter contre les surcharges adipeuses, et pour en atténuer les effets disgracieux. Fat overloads are defects that can affect the aesthetic appearance of the individual, and they also constitute abnormal physiological states in humans, but especially in women, where accumulations of cellulite are still considered unsightly. These conditions, although different from obesity, usually require systemic treatment. Often, in the absence of therapeutic treatment, a cosmetic treatment is desired to fight against fat overload, and to mitigate the unsightly effects.
Aussi, il existe un besoin constant de mettre au point des compositions susceptibles de procurer un effet lipolytique utile dans le traitement des surcharges adipeuses, tant sur les plans cosmétiques que thérapeutique. L'effet lipolytique d'une substance peut s'évaluer par sa capacité à déstocker les lipides adipocytaires en augmentant la concentration intercellulaire d'AMP cyclique (AMPc). Cette augmentation est dépendante de la saturation des récepteurs du neuropeptide Y et des récepteurs a2adrénergiques. En effet, lorsque le neuropeptide Y ou les prostanoïdes se fixent sur leurs récepteurs, ils induisent une diminution de l'AMPc, qui entraîne une diminution de l'activité des lipases, et une augmentation de l'accumulation des lipides adipocytaires. Also, there is a constant need to develop compositions that can provide a lipolytic effect useful in the treatment of fat overload, both cosmetically and therapeutically. The lipolytic effect of a substance can be evaluated by its ability to destock adipocyte lipids by increasing the intercellular concentration of cyclic AMP (cAMP). This increase is dependent on the saturation of neuropeptide Y receptors and α 2 adrenergic receptors. Indeed, when neuropeptide Y or prostanoids bind to their receptors, they induce a decrease in cAMP, which leads to a decrease in the activity of lipases, and an increase in the accumulation of adipocyte lipids.
L'huile de chaulmoogra a longtemps été utilisée en médecine traditionnelle en Asie, notamment en Inde et en Chine, pour le traitement de la lèpre, avant l'apparition de médicaments à base de sulfones, notamment la diaminodiphénylsulfone, et des antibiotiques antituberculeux tels que la rifampicine et la rifamycine. Il a été démontré que l'acide hydnocarpique, l'un des principaux constituants de l'huile de chaulmoogra, présente une activité antimycobactérienne en inhibant la multiplication de certaines mycobactéries telles que Mycobacterium leprae, comme indiqué par P.L. Jacobsen et L. Levy, Antimycobacterial Agents and Chemotherapy (1973) pp. 373-379. Chaulmoogra oil has long been used in traditional medicine in Asia, particularly in India and China, for the treatment of leprosy, before the emergence of sulfonated drugs, including diaminodiphenylsulfone, and antituberculous antibiotics such as rifampicin and rifamycin. Hydnocarpic acid, one of the main constituents of chaulmoogra oil, has been shown to exhibit antimycobacterial activity by inhibiting the growth of certain mycobacteria, such as Mycobacterium leprae, as indicated by PL Jacobsen and L. Levy, Antimycobacterial Agents and Chemotherapy (1973) pp. 373-379.
Plus récemment, leur utilisation comme composant de compositions cosmétiques a été décrite, par exemple dans le brevet FR 2.706.304 relatif à des compositions destinées à harmoniser la pigmentation de la peau, grâce aux effets de pigmentation des zones cutanées achromiques, c'est-à-dire peu ou pas pigmentées, par migration de la pigmentation à partir de zones pigmentées. Le brevet FR 2.518.402 décrit une composition contenant de l'huile de chaulmoogra utilisable en cosmétique pour la normalisation des sécrétions sébacées et de la flore microbienne cutanée. L'utilisation des huiles de chaulmoogra dans des lotions capillaires destinées à favoriser la repousse des cheveux a aussi été décrite dans le brevet BE 570.171. More recently, their use as a component of cosmetic compositions has been described, for example in patent FR 2 706 304 relating to compositions intended to harmonize the pigmentation of the skin, by virtue of the pigmentation effects of the achromic cutaneous zones, that is, ie, little or no pigmented, by migration of pigmentation from pigmented areas. Patent FR 2,518,402 describes a composition containing chaulmoogra oil that can be used in cosmetics for the normalization of sebaceous secretions and cutaneous microbial flora. The use of chaulmoogra oils in hair lotions intended to promote the regrowth of hair has also been described in patent BE 570.171.
Les huiles de chaulmoogra, sont essentiellement extraites des graines de plantes ligneuses des régions tropicales appartenant à la famille des Flacourtiacées, notamment d'un arbre de variétés telles que Hydnocarpus wightiana et Taraktogenos kurzii. Ces plantes sont essentiellement d'origine asiatique, notamment d'Inde, du Viet-nam et des Philippines, ainsi que d'Afrique centrale et d'Amérique du sud, notamment du Brésil. The oils of chaulmoogra, are essentially extracted from the seeds of woody plants of the tropical regions belonging to the family Flacourtiacées, in particular of a tree of varieties such as Hydnocarpus wightiana and Taraktogenos kurzii. These plants are mainly of Asian origin, including India, Vietnam and the Philippines, as well as Central and South America, including Brazil.
Les graines d'où sont extraites les huiles de chaulmoogra contiennent une forte proportion de lipides, comprise entre 30 et 50% selon les espèces, 15 à 20% de protides et 4 à 6% de matière minérales, ainsi que 1 à 3% d'insaponifiables, des glycérides d'acides gras insaturés à cycle penténique, consti- tués essentiellement par l'acide chaulmoogrique, l'acide hydnocarpique et l'acide gorlique. Il semble que ces acides soient responsables de l'action antimycobactérienne utile en thérapeutique dans le traitement traditionnel de la lèpre. On a observé que la structure spatiale de ces acides se rapproche du noyau cyclopentanoperhydroxyphénantrène caractéristique des stérols. The seeds from which the chaulmoogra oils are extracted contain a high proportion of lipids, between 30 and 50% depending on the species, 15 to 20% of proteins and 4 to 6% of mineral matter, as well as 1 to 3% of unsaponifiable glycerides of unsaturated pentenic-substituted fatty acids, consisting essentially of chaulmoogric acid, hydnocarpic acid and gorlic acid. It seems that these acids are responsible for the therapeutic antimycobacterial action in the traditional treatment of leprosy. It has been observed that the spatial structure of these acids is similar to the cyclopentanoperhydroxyphenantrene ring characteristic of sterols.
Les acides chaulmoogrique, hydnocarpique et gorlique peuvent être représentés par les formules générales suivantes, respectivement: ca)1zCOOH = CH - !+( - COOH Ainsi, ces trois acides comprennent le même cycle cyclopenténique portant un groupe acide à l'extrémité d'une Io chaîne carbonée -(CH2)n- où n est 10 dans le cas de l'acide hydnocarpique et 12 dans le cas de l'acide chaulmoogrique, cette même chaîne comportant une double liaison dans le cas de l'acide gorlique. Les teneurs en chacun de ces trois acides dans les huiles de chaulmoogra dépendent de l'origine des espèces. The chaulmoogic, hydnocarpic and gorlic acids may be represented by the following general formulas, respectively: ## STR1 ## Thus, these three acids comprise the same cyclopentenic ring carrying an acid group at the end of a Io carbon chain - (CH2) n- where n is 10 in the case of hydnocarpic acid and 12 in the case of chaulmoogric acid, this same chain having a double bond in the case of gorlic acid. in each of these three acids in chaulmoogra oils depend on the origin of the species.
Des esters de ces acides, en particulier des esters méthyliques, éthyliques et benzyliques, ont été synthétisés en vue d'en améliorer l'acceptabilité et la tolérance. De même on a constaté que des sels tels que le chaulmoograte de sodium et l'hydnocarpate de sodium, exercent une action dissolvante sur les lécithines et le cholestérol, ce qui pourrait expliquer leur action sur l'enveloppe cireuse des bacilles de la lèpre et de la tuberculose. Esters of these acids, in particular methyl, ethyl and benzyl esters, have been synthesized with a view to improving their acceptability and tolerance. In the same way, it has been found that salts such as sodium chaulmoograte and sodium hydnocarpate exert a dissolving action on lecithins and cholesterol, which could explain their action on the waxy envelope of the bacilli of leprosy and tuberculosis.
On trouve également dans les huiles de chaulmoogra des acides gras du type palmitique, oléique, palmitoléique, stéarique, myristique, et des traces d'acide aleprique et aleprilique. Chaulmoogra oils also contain fatty acids such as palmitic, oleic, palmitoleic, stearic, myristic, and traces of alepric and aleprylic acid.
Les études réalisées par la demanderesse sur les récepteurs cellulaires et la protection des cellules dendri- tiques ont maintenant démontré de manière inattendue que l'huile de chaulmoogra présente un effet lipolytique vérifié par son action sur les adipocytes humains en culture, se traduisant par la compétition de cette huile, appliquée par voie externe, vis-à-vis des récepteurs du neuropeptide Y et a2 adrénergiques. Applicant studies on cell receptors and protection of dendritic cells have now unexpectedly demonstrated that chaulmoogra oil has a lipolytic effect verified by its action on cultured human adipocytes, resulting in competition. of this oil, applied externally, vis-à-vis neuropeptide receptors Y and a2 adrenergic.
La présente invention a donc pour objet une nouvelle utilisation de l'huile de chaulmoogra et/ou de ses composants en une concentration appropriée, pour préparer des composi- tions cosmétiques et pharmaceutiques destinées au traitement et à la prévention des surcharges adipeuses et de la cellulite. The present invention therefore relates to a new use of chaulmoogra oil and / or its components in a suitable concentration, to prepare cosmetic and pharmaceutical compositions for the treatment and prevention of fat overload and cellulite. .
L'invention a également pour objet l'utilisation de l'huile de chaulmoogra, ou de ses composants essentiels tels que les acides chaulmoogrique, hydnocarpique et gorlique, ainsi que leurs sels et esters, pour la préparation d'une composition cosmétique pour le traitement des surcharges adipeuses et de la cellulite. The invention also relates to the use of chaulmoogra oil, or its essential components such as chaulmoogric, hydnocarpic and gorlic acids, as well as their salts and esters, for the preparation of a cosmetic composition for the treatment fat overload and cellulite.
L'invention a aussi pour objet l'utilisation de l'huile de chaulmoogra, et/ou de ses composants essentiels tels que les acides chaulmoogrique, hydnocarpique et gorlique, ainsi que leurs sels et esters, pour la préparation d'un médicament à effet lipolytique pour le traitement des surcharges adipeuses et de la cellulite. The invention also relates to the use of chaulmoogra oil, and / or its essential components such as chaulmoogric, hydnocarpic and gorlic acids, as well as their salts and esters, for the preparation of an effect medicine. lipolytic for the treatment of fat overload and cellulite.
L'invention a encore pour objet un procédé de traitement cosmétique de la peau, et plus particulièrement pour prévenir ou réduire les surcharges adipeuses et la cellulite, par application d'une composition à base d'huile de chaulmoogra sur la zone de la peau nécessitant un tel traitement. The subject of the invention is also a process for the cosmetic treatment of the skin, and more particularly for preventing or reducing adipose overloads and cellulite, by applying a composition based on chaulmoogra oil on the area of the skin requiring such a treatment.
Les expérimentations effectuées ont montré que l'activité lipolytique de l'huile de chaulmoogra était essentiellement due aux acides chaulmoogrique, hydnocarpique et gorlique qu'elle contient. L'invention s'étend donc à l'utilisation de l'huile de chaulmoogra et/ou des acides chaulmoogrique, hydnocarpique et gorlique, ainsi que de leurs sels ou esters tels que par exemple leurs esters de méthyle, d'éthyle ou de benzyle, ainsi que les sels de sodium ou de potassium, et par exemple le chaulmoograte de sodium ou de potassium et l'hydnocarpate de sodium. Experiments have shown that the lipolytic activity of chaulmoogra oil is mainly due to the chaulmoogric, hydnocarpic and gorlic acids it contains. The invention therefore extends to the use of chaulmoogra oil and / or chaulmoogric, hydnocarpic and gorlic acids, as well as their salts or esters, such as, for example, their methyl, ethyl or benzyl esters. as well as sodium or potassium salts, and for example sodium or potassium chaulmoograte and sodium hydnocarpate.
Plus particulièrement, il a été démontré que - une composition à base d'huile de chaulmoogra procure une protection vis-à-vis de l'inhibition du TNFa (facteur onconécrosant) dès la concentration de 0,5 à 1%, ce qui laisse supposer une action sur les prostanoïdes, et par conséquent sur la lipogénèse. More particularly, it has been demonstrated that - a composition based on chaulmoogra oil provides protection against inhibition of TNFα (tumor necrosis factor) from the concentration of 0.5 to 1%, which leaves suppose an action on prostanoids, and consequently on lipogenesis.
- les prostanoïdes tels que la prostaglandine E2 sont des molécules qui stimulent la lipogénèse après fixation sur les récepteurs des adipocytes, et cette stimulation est médiée par la phospholipase C. Aussi, comme indiqué plus loin, l'effet lipolytique de l'huile de chaulmoogra est démontré par son effet de blocage de la fixation des prostanoïdes sur leur récepteur par compétition avec eux. prostanoids such as prostaglandin E2 are molecules that stimulate lipogenesis after binding to adipocyte receptors, and this stimulation is mediated by phospholipase C. Also, as indicated below, the lipolytic effect of chaulmoogra oil is demonstrated by its blocking effect of prostanoid binding on their receptor by competition with them.
- le neuropeptide Y est un neurotransmetteur qui stimule la pénétration des glucides par les adipocytes après fixation sur son récepteur, et cette accumulation de glucides par les cellules des tissus adipeux augmente leur capacité à synthétiser et à stocker les lipides. Or, les études effectuées par la demanderesse ont montré que l'huile de chaulmoogra entre en compétition avec le récepteur du neuropeptide Y et possède donc une activité lipolytique. neuropeptide Y is a neurotransmitter that stimulates carbohydrate penetration by adipocytes after attachment to its receptor, and this accumulation of carbohydrates by adipose tissue cells increases their ability to synthesize and store lipids. However, the studies carried out by the Applicant have shown that chaulmoogra oil competes with the neuropeptide Y receptor and therefore has lipolytic activity.
Les huiles de chaulmoogra utilisées dans les compositions de la présente invention peuvent être extraites des graines de plantes de variétés telles que Hydnocarpus wightiana, Taraktogenos kurzii, Hydnocarpus alpina, Hydnocarpus anthelmintica, Hydnocarpus cauliflora, Hydnocarpus dawnensis, Hydnocarpus heterophylla, Hydnocarpus hutchinsonii, Hydnocarpus ovoïdea, Hydnocarpus subfalcata, Hydnocarpus venenata, Hydnocarpus verrucosa, Hydnocarpus woodii, Hydnocarpus calvipetala, Hydnocarpus ilicifolia, Hydnocarpus octandra, Gynocardia odorata, Oncoba echinata, Caloncoba glauca, Caloncoba welwitschii, Carpotroche brasiliensis, Carpotroche amazonica, Asteriastigma macrocarpa, Mayna odorata et Lindakeria dentata. The chaulmoogra oils used in the compositions of the present invention can be extracted from the seeds of plants of varieties such as Hydnocarpus wightiana, Taraktogenos kurzii, Hydnocarpus alpina, Hydnocarpus anthelmintica, Hydnocarpus cauliflora, Hydnocarpus dawnensis, Hydnocarpus heterophylla, Hydnocarpus hutchinsonii, Hydnocarpus ovoidea, Hydnocarpus subtacata, Hydnocarpus venenata, Hydnocarpus verrucosa, Hydnocarpus woodii, Hydnocarpus calvipetala, Hydnocarpus ilicifolia, Hydnocarpus octandra, Gynocardia odorata, Oncoba echinata, Caloncoba glauca, Caloncoba welwitschii, Carpotroche brasiliensis, Carpotroche amazonica, Asteriastigma macrocarpa, Mayna odorata and Lindakeria dentata.
Préparation des adipocytes humains en culture L'étude a été réalisée sur des adipocytes humains en culture, par la méthode de la liaison du neuropeptide Y et des prostanoïdes sur leurs récepteurs au niveau de la cellule adipocytaire. Preparation of human adipocytes in culture The study was carried out on human adipocytes in culture, by the method of the binding of neuropeptide Y and prostanoids on their receptors at the level of the adipocyte cell.
Les adipocytes sont obtenus par prélèvement du tissu adipeux à partir d'une chirurgie plastique (peau entière), conservé à température ambiante dans un milieu de conservation approprié puis découpé finement et placé dans un tampon HBSS à pH 7,4. Une solution de collagénase de type II (1 mg/ml dans le tampon HBSS à pH 7,4) est ajoutée au tube contenant les fragments de tissu adipeux (4 volumes de collagénase pour 1 volume de tissu) et l'ensemble est incubé à 37 C pendant 40 à 60 minutes sous agitation constante, sans dioxyde de carbone. Cette première étape permet de libérer les adipocytes de la gangue conjonctive et du stroma vasculaire. The adipocytes are obtained by taking adipose tissue from plastic surgery (whole skin), stored at room temperature in a suitable preservation medium and then finely cut and placed in an HBSS buffer at pH 7.4. A solution of collagenase type II (1 mg / ml in HBSS buffer pH 7.4) is added to the tube containing the adipose tissue fragments (4 volumes of collagenase per 1 volume of tissue) and the whole is incubated at 37 C for 40 to 60 minutes with constant stirring, without carbon dioxide. This first step releases the adipocytes from the conjunctival gangue and vascular stroma.
Après incubation, les cellules sont récupérées par filtration sur un filtre en nylon et les adipocytes ainsi isolés sont séparés par flottation. Après élimination du sous-nageant par aspiration, la suspension adipocytaire est lavée par un tampon isotonique KBR pour éliminer toute trace de collagénase. Après addition de 3,5% de BSA, le pH est ajusté à 7,5 et le tampon est filtré (filtre 0,22 pm). After incubation, the cells are recovered by filtration on a nylon filter and the adipocytes thus isolated are separated by flotation. After removal of the subnant by suction, the adipocyte suspension is washed with a KBR isotonic buffer to remove any trace of collagenase. After addition of 3.5% BSA, the pH is adjusted to 7.5 and the buffer is filtered (0.22 μm filter).
Compétition vis-à-vis des récepteurs a-2 adrénergiques Les prostanoïdes comme la prostaglandine E2 sont des molécules qui stimulent la lipogénèse après fixation sur les récepteurs des adipocytes. Une méthode pour démontrer l'effet lipolytique d'une substance consiste donc à bloquer la fixation des prostanoïdes sur leur récepteur par compétition avec eux. Competition with α-2 adrenergic receptors Prostanoids such as prostaglandin E2 are molecules that stimulate lipogenesis after binding to adipocyte receptors. A method for demonstrating the lipolytic effect of a substance therefore consists in blocking the binding of prostanoids to their receptor by competition with them.
L'effet de compétition de l'huile de chaulmoogra de l'invention vis-à-vis des récepteurs a-2 adrénergiques est vérifié comme indiqué ci-après. The competition effect of the chaulmoogra oil of the invention with respect to the α-2 adrenergic receptors is verified as indicated below.
Les adipocytes humains en culture sont répartis en plusieurs lots incubés pendant 1 heure sous agitation. La réaction de liaison est réalisée en présence de HC-PGE2 (43,8 Ci/mmol). Le lot n 1 est un témoin négatif ne contenant pas d'huile de chaulmoogra et sans traitement. Le lot n 2 est un témoin positif ne contenant pas d'huile de chaulmoogra et soumis au traitement. Les lots n 3, n 4 et n 5 contiennent respectivement 0,5%, 1% et 5% en poids d'huile de chaulmoogra suivant l'invention. The human adipocytes in culture are distributed in several batches incubated for 1 hour with stirring. The binding reaction is carried out in the presence of HC-PGE2 (43.8 Ci / mmol). Lot # 1 is a negative control that does not contain chaulmoogra oil and is untreated. Lot 2 is a positive control that does not contain chaulmoogra oil and is subjected to treatment. Batches n 3, n 4 and n 5 contain respectively 0.5%, 1% and 5% by weight of chaulmoogra oil according to the invention.
Le tableau 1 des résultats indiqués ci-dessous montre que l'huile de chaulmoogra entre en compétition avec la PGE2 et bloque la fixation sur les récepteurs des adipocytes dès la concentration de 0,5% en poids. Table 1 of the results indicated below shows that chaulmoogra oil competes with PGE2 and blocks the binding to adipocyte receptors at a concentration of 0.5% by weight.
Tableau 1Table 1
Cpm écart type Variation % Témoin (lot n 2) 10529 145 Huile de chaulmoogra à 7817 229 - 25 0,5% (lot 3) Huile de chaulmoogra à 5118 303 - 51 1% (lot 4) Huile de chaulmoogra à 5007 196 - 52 5% (lot 5) Les résultats sont exprimés en coups par minute (Cpm). Cpm standard deviation Variation% Control (lot 2) 10529 145 Oil of chaulmoogra 7817 229 - 25 0.5% (lot 3) Oil of chaulmoogra at 5118 303 - 51 1% (lot 4) Oil of chaulmoogra at 5007 196 - 52 5% (lot 5) The results are expressed in counts per minute (Cpm).
Compétition vis-à-vis du récepteur du neuropeptide Y L'effet de compétition de l'huile de chaulmoogra de l'invention vis-à-vis du récepteur du neuropeptide Y est vérifié comme indiqué ci-après. Competition with respect to the neuropeptide Y receptor The competition effect of the chaulmoogra oil of the invention with respect to the neuropeptide Y receptor is checked as indicated below.
Les adipocytes sont répartis en plusieurs lots comme indiqué ci-dessus, mais la réaction de liaison est réalisée en présence de 125I-NY (73,3 Ci/mmol). The adipocytes are distributed in several batches as indicated above, but the binding reaction is carried out in the presence of 125 I-NY (73.3 Ci / mmol).
On sait que le neuropeptide Y est un neurotransmetteur qui stimule la pénétration des glucides par les adipocytes après fixation sur son récepteur. Les résultats indiqués au tableau 2 ci-dessous montrent que l'huile de chaulmoogra entre en compétition avec le neuropeptide Y et bloque sa fixation sur son récepteur dès la concentration de 0,5% en poids, en limitant sa capacité à synthétiser et stocker des lipides. Neuropeptide Y is known to be a neurotransmitter that stimulates carbohydrate penetration by adipocytes after attachment to its receptor. The results shown in Table 2 below show that chaulmoogra oil competes with neuropeptide Y and blocks its binding to its receptor at a concentration of 0.5% by weight, limiting its ability to synthesize and store proteins. lipids.
Tableau 2Table 2
Cpm écart type Variation % Témoin (lot n 2) 7280 315 Huile de chaulmoogra à 6412 251 - 12 0,5% (lot 3) Huile de chaulmoogra à 5032 111 - 30 1% (lot 4) Huile de chaulmoogra à 4805 98 - 33 5% (lot 5) Ces résultats mettent en évidence l'effet lipolytique des huiles de chaulmoogra de l'invention, dès la concentration de 15 0,5% en poids. Cpm standard deviation Variation% Control (lot 2) 7280 315 Chaulmoogra oil at 6412 251 - 12 0.5% (lot 3) Chaulmoogra oil at 5032 111 - 30 1% (lot 4) Chaulmoogra oil at 4805 98 - 33 5% (lot 5) These results highlight the lipolytic effect of the chaulmoogra oils of the invention, from the concentration of 0.5% by weight.
La teneur en huile de chaulmoogra, ou en acides ou sels ou esters des compositions suivant la présente invention est généralement comprise entre 0,1 et 20%, et de préférence entre 1 et 10% par rapport au poids total de la composition, pour procurer les meilleurs effets lipolytiques. The oil content of chaulmoogra, or of acids or salts or esters of the compositions according to the present invention is generally between 0.1 and 20%, and preferably between 1 and 10% relative to the total weight of the composition, to provide the best lipolytic effects.
Les compositions conformes à la présente invention sont de préférence administrables par voie topique. Suivant la terminologie classique, l'administration par voie topique désigne toute méthode consistant à appliquer la substance ou la composition directement sur la peau, sur la zone nécessitant le traitement. The compositions according to the present invention are preferably topically administrable. In conventional terminology, topical administration refers to any method of applying the substance or composition directly to the skin on the area requiring treatment.
Conformément à la présente invention, la composition administrable par voie topique peut avantageusement contenir, outre les composants de base décrits ci-dessus, une ou plusieurs autres substances connues pour exercer des effets complémentaires bénéfiques pour la peau, et plus particulièrement le tocophérol, la vitamine A (rétinol), l'acide rétinoïque, des agents bactéricides, de la théophylline ainsi que des extraits végétaux connus pour favoriser l'effet d'amincissement comme des extraits huileux de thé vert et de café vert, des extraits huileux de Garcinia cambodgiana ou de Chondrus crispus, ou un extrait alcoolique de lierre ou de liane du Pérou, ou des agents drainants tels que des mucopolysaccharides et par exemple des extraits de laminaria digitata. In accordance with the present invention, the topically administrable composition may advantageously contain, in addition to the basic components described above, one or more other substances known to have beneficial effects on the skin, and more particularly tocopherol, vitamin A (retinol), retinoic acid, bactericidal agents, theophylline as well as plant extracts known to promote the thinning effect such as oily extracts of green tea and green coffee, oily extracts of Garcinia cambodgiana or Chondrus crispus, or an alcoholic extract of ivy or vine of Peru, or draining agents such as mucopolysaccharides and for example extracts of Laminaria digitata.
Les compositions cosmétiques et pharmaceutiques conformes à la présente invention, sont destinées de préférence à une administration topique, et contiennent donc des supports et excipients couramment utilisés dans des compositions de ce type telles que des émulsions H/E ou E/H, des crèmes, des gels ou des lotions. Dans le cas des émulsions, la phase grasse peut représenter entre 10 et 60% environ du poids de la composition, la phase aqueuse entre 10 et 80% environ et l'agent émulsionnant entre 2 et 20%, le reste étant constitué par les composants de base indiqués ci-dessus et les autres composants mentionnés ci-après. The cosmetic and pharmaceutical compositions in accordance with the present invention are preferably intended for topical administration, and therefore contain carriers and excipients commonly used in compositions of this type, such as O / W or W / O emulsions, creams, gels or lotions. In the case of emulsions, the fatty phase may represent between 10 and 60% of the weight of the composition, the aqueous phase between 10 and 80% and the emulsifier between 2 and 20%, the remainder being constituted by the components above and the other components listed below.
La composition peut encore contenir diverses substances et excipients choisis en fonction de leurs propriétés connues et de la forme galénique envisagée. Ainsi, on peut incorporer dans la composition des conservateurs, des agents émul- sionnants, des agents viscosants, des épaississants, des gélifiants, des antioxydants, des agents hydratants, des tensioactifs, des parfums, des huiles, des lipides, un solvant spécifique ainsi que de l'eau et divers additifs destinés à améliorer les propriétés physiques de la composition. The composition may also contain various substances and excipients chosen according to their known properties and the intended dosage form. Thus, preservatives, emulsifiers, viscosifiers, thickeners, gelling agents, antioxidants, moisturizers, surfactants, perfumes, oils, lipids, a specific solvent and the like can be incorporated into the composition. only water and various additives to improve the physical properties of the composition.
On peut choisir l'agent émulsionnant parmi des polymères carboxyvinyliques à haut poids moléculaire (par exemple le Carbopol ), des polysorbates (par exemple le Tween 20 ou le Polysorbate 80 ), des esters de sorbitan et en particulier un monostéarate, un tristéarate, un monopalmitate, et un laurate de sorbitan. On peut encore utiliser d'autres agents émulsionnants tels que divers dérivés d'acide stéarique ou palmitique, et par exemple le stéarate de PEG 100 , des mono- ou diglycérides d'acide stéarique ou palmitique, un stéarate de propylène glycol auto-émulsionnable, ou encore le poly- glycéryl-2-sesquioléate, l'éther cétylique de polyoxyéthylène, un polyglucoside de siloxane, ou une silicone émulsionnable. The emulsifier may be selected from high molecular weight carboxyvinyl polymers (eg, Carbopol), polysorbates (eg, Tween 20 or Polysorbate 80), sorbitan esters, and especially a monostearate, a tristearate, a monopalmitate, and a sorbitan laurate. Other emulsifying agents may also be used, such as various stearic or palmitic acid derivatives, and for example PEG 100 stearate, mono- or diglycerides of stearic or palmitic acid, self-emulsifiable propylene glycol stearate, or alternatively polyglyceryl-2-sesquioleate, polyoxyethylene cetyl ether, a siloxane polyglucoside, or an emulsifiable silicone.
On peut encore utiliser des mélanges émulsionnants non ioniques tels que le Protegin X . Nonionic emulsifying mixtures such as Protegin X may also be used.
Les agents viscosants utilisés dans les compositions de l'invention peuvent être choisis parmi divers polymères d'acide acrylique, un coppolymère d'acrylate et de laurate d'acryloyle, une gomme cellulose, une silice, des polymères carboxyvinyliques, un silicate d'aluminium et de magnésium, et on peut utiliser par exemple la silice colloïdale vendue sous la marque Aerosil 200 ou un acide polyacrylique réticulé tel que le Carbopol 940 . The viscosifying agents used in the compositions of the invention may be chosen from various polymers of acrylic acid, a copolymer of acrylate and acryloyl laurate, a cellulose gum, a silica, carboxyvinyl polymers, an aluminum silicate and magnesium, and it is possible to use, for example, the colloidal silica sold under the trademark Aerosil 200 or a crosslinked polyacrylic acid such as Carbopol 940.
Les gélifiants ou épaississants peuvent être choisis par exemple parmi les polyacrylamides, des acrylates comme le Pemulen , les dérivés de cellulose comme l'hydroxypropyl cellulose, ou les gommes naturelles. The gelling agents or thickeners may be chosen for example from polyacrylamides, acrylates such as Pemulen, cellulose derivatives such as hydroxypropyl cellulose, or natural gums.
Les agents hydratants utilisés peuvent être choisis par exemple parmi un polyol, le sorbitol, le maltitol, le pentaérythritol, les polyacrylates et polyméthacrylates de glycéryle, le glycérol ou des dérivés de glycérol. On peut aussi ajouter des émollients tels qu'un malate d'alkyle, l'isohexadécane, des triglycérides d'acide caprique ou caprylique, etc. Les conservateurs usuels de la technique des compositions dermatologiques ou cosmétologiques peuvent être utilisés dans l'invention, et par exemple l'acide benzoïque et un phydroxybenzoate d'alkyle tel que les p-hydroxybenzoates de méthyle et de propyle (Méthylparaben et Propylparaben), un alcool tel que le phénoxy-éthanol ou encore la chlorphénésine ou l'imidazolidinyl urée. The moisturizing agents used may be chosen for example from a polyol, sorbitol, maltitol, pentaerythritol, glyceryl polyacrylates and polymethacrylates, glycerol or glycerol derivatives. It is also possible to add emollients such as alkyl malate, isohexadecane, capric or caprylic acid triglycerides, etc. The usual preservatives of the technique of dermatological or cosmetological compositions can be used in the invention, and for example benzoic acid and an alkyl phydroxybenzoate such as methyl and propyl p-hydroxybenzoates (Methylparaben and Propylparaben), a alcohol such as phenoxyethanol or chlorphenesine or imidazolidinyl urea.
lo Les constituants de la phase grasse, c'est-à-dire les huiles et lipides, peuvent être choisis parmi l'huile de jojoba, l'huile de maïs, l'huile de vaseline, l'huile de coco hydrogénée, l'huile de carthame, des glycérides d'acides gras saturés, l'acide stéarique, l'acide palmitique, le stéarate d'octyle, le palmitate de glycéryle, le palmitate d'octyle, un triglycéride d'acides caprique et caprylique, le 2-octyldodécanol, le polyéthylène glycol, l'adipate d'éthyl-2 hexyle, ou encore des huiles de silicones telles que le méthyl phényl polysiloxane, la diméthicone, la cyclométhicone, la cyclo- méthicone/diméthicone copolyol, la phényl diméthicone. The constituents of the fatty phase, that is to say the oils and lipids, can be chosen from jojoba oil, corn oil, liquid petroleum jelly, hydrogenated coconut oil safflower oil, saturated fatty acid glycerides, stearic acid, palmitic acid, octyl stearate, glyceryl palmitate, octyl palmitate, capric and caprylic acid triglyceride, 2-octyldodecanol, polyethylene glycol, 2-ethylhexyl adipate, or silicone oils such as methyl phenyl polysiloxane, dimethicone, cyclomethicone, cyclomethicone / dimethicone copolyol, phenyl dimethicone.
La composition peut aussi contenir un solvant choisi en fonction des composants utilisés et de la forme d'administration envisagée. Le solvant peut être par exemple de l'eau, et de préférence de l'eau déminéralisée, ou un solvant spécifique tel que le propylène glycol, un éther de diéthylène glycol, ou un alcool, en particulier l'éthanol. The composition may also contain a solvent chosen according to the components used and the intended form of administration. The solvent may be, for example, water, and preferably deionized water, or a specific solvent such as propylene glycol, a diethylene glycol ether, or an alcohol, in particular ethanol.
Le pH de la composition est de préférence compris entre 5,5 et 7,5, et peut être ajusté, selon les compositions, par addition d'un acide tel que l'acide citrique ou d'une base telle que l'hydroxyde de sodium. The pH of the composition is preferably between 5.5 and 7.5, and may be adjusted, depending on the compositions, by the addition of an acid such as citric acid or a base such as hydroxide. sodium.
La composition conforme à la présente invention peut être présentée sous les formes classiquement utilisées pour une application topique, c'est-àdire sous forme de gel, lotion, émulsion (en particulier crème ou lait), masque ou pommade, contenant des excipients et supports usuels compatibles et pharmaceutiquement acceptables. Ces formes d'administration par voie topique sont préparées par les techniques connues, et par exemple, dans le cas d'une crème, par dispersion d'une phase grasse dans une phase aqueuse pour obtenir une émulsion huile dans eau, ou inversement pour préparer une émulsion eau dans huile. Dans le cas de crèmes, on préfère utiliser des émulsions à structure lamellaire contenant peu de produits éthoxylés ou n'en contenant pas du tout. L'huile de chaulmoogra est de préférence préalablement chauffée avant d'être Io incorporée à la phase grasse. The composition according to the present invention may be presented in the forms conventionally used for a topical application, that is to say in the form of a gel, lotion, emulsion (in particular cream or milk), mask or ointment, containing excipients and carriers. customary compatible and pharmaceutically acceptable. These forms of topical administration are prepared by the known techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion. In the case of creams, it is preferred to use lamellar structure emulsions containing little or no ethoxylated products. The oil of chaulmoogra is preferably preheated before being incorporated in the fat phase.
A titre d'exemple, on peut préparer des compositions topiques conformes à l'invention sous forme de crèmes amincissantes, de laits ou de gels amincissants, utilisables en une ou plusieurs applications quotidiennes, la durée du traitement pouvant être généralement de l'ordre de un à trois mois. By way of example, it is possible to prepare topical compositions in accordance with the invention in the form of slimming creams, milks or slimming gels, which can be used in one or more daily applications, the duration of the treatment being generally of the order of one to three months.
Les exemples de compositions à base d'huile de chaulmoogra donnés ciaprès illustrent l'invention sans en limiter la portée. Sauf indication contraire, les parties et pourcentage sont indiqués en poids. The following examples of chaulmoogra oil compositions illustrate the invention without limiting its scope. Unless otherwise indicated, parts and percentages are by weight.
Exemple 1Example 1
Un gel amincissant à base d'huile de chaulmoogra ayant la composition indiquée ci-après est préparé suivant les techniques usuelles: huile de chaulmoogra 5,0 EDTA trisodique 0,1 glycérine 2,0 octyldodécanol 2,0 polymère carboxyvinylique 0,5 oléate de décyle 2,0 copolymère acrylate de sodium / laurate de diméthyl acryloyle 0,5 trométhamine 0,6 phényl diméthicone 1,0 extrait de laminaria digitata 7,0 extrait de liane du Pérou 3,0 parfum 0,1 conservateurs 0,6 Eau déminéralisée q.s.p. 100,00 Ce gel amincissant est utilisé en application topique, une fois par jour sur les zones de la peau à traiter, pendant une période de 8 semaines. Les premiers effets peuvent être observés dès la fin de la 2ème semaine, sous forme de diminu- tion significative des capitons graisseux. Une réduction de 0,2 à 2 cm de tour de cuisse est constatée en fin de 4ème semaine de traitement, et de 0,4 à 2,5 cm en fin de 8ème semaine chez 60% des volontaires suivant le traitement. A slimming gel based on chaulmoogra oil having the composition indicated below is prepared according to the usual techniques: chaulmoogra oil 5.0 trisodium EDTA 0.1 glycerine 2.0 octyldodecanol 2.0 carboxyvinyl polymer 0.5 oleate decyle 2.0 copolymer sodium acrylate / dimethyl acryloyl laurate 0.5 tromethamine 0.6 phenyl dimethicone 1.0 extract of laminaria digitata 7.0 extract of liana from Peru 3.0 perfume 0.1 preservatives 0.6 Demineralized water qs 100,00 This slimming gel is used topically, once a day on the areas of the skin to be treated, for a period of 8 weeks. The first effects can be observed as early as the end of the 2nd week, in the form of a significant decrease in fatty starches. A reduction of 0.2 to 2 cm of round of thigh is observed at the end of the 4th week of treatment, and from 0.4 to 2.5 cm at the end of the 8th week in 60% of the volunteers following the treatment.
Exemple 2Example 2
Une huile drainante amincissante à base d'huile de chaulmoogra ayant la composition indiquée ci-après est préparée suivant les techniques usuelles: huile de chaulmoogra 5,0 extrait huileux de thé vert 5,0 extrait huileux de café vert 5,0 extrait huileux de Garcinia cambodgiana 5,0 extrait huileux de Chondrus crispus 5,0 huile de noisette 1,0 huile de camélia 30,0 isohexadécane 20,0 parfum 1,0 triglycéride caprique / caprylique qsp 100,0 Les extraits huileux utilisés dans la composition cidessus sont obtenus dans un mélange de triglycérides caprique / caprylique. A slimming draining oil based on chaulmoogra oil having the composition indicated below is prepared according to the usual techniques: chaulmoogra oil 5.0 oily green tea extract 5.0 oily green coffee extract 5.0 oily extract Garcinia cambodgiana 5.0 oily extract of Chondrus crispus 5.0 hazelnut oil 1.0 camellia oil 30.0 isohexadecane 20.0 perfume 1.0 triglyceride capric / caprylic qs 100.0 The oily extracts used in the composition above are obtained in a mixture of capric / caprylic triglycerides.
Exemple 3Example 3
Une crème amincissante à base d'huile de chaulmoogra ayant la composition indiquée ci-après est préparée suivant les techniques usuelles: huile de chaulmoogra 3,0 glycérine 2,0 EDTA trisodique 0,1 butylène glycol 4,0 gomme xanthane 0,2 cétéaryl glucoside 4,0 alcool cétylique 1,0 tristéarine 0,8 stéarate d'acétyl glycol 0,8 phényl diméthicone 1,0 cyclopentasiloxane 4,0 tocophérol 0,7 copolymère acrylate de sodium / laurate de diméthyl acryloyle 0,5 isohexadécane 0,3 Polysorbate 80 0,8 extrait glycolique de lierre 2,0 théophylline 1,0 conservateurs 0,8 parfums 0,1 Eau déminéralisée q.s.p. 100,00 A slimming cream based on chaulmoogra oil having the composition indicated below is prepared according to the usual techniques: chaulmoogra oil 3.0 glycerin 2.0 trisodium EDTA 0.1 butylene glycol 4.0 xanthan gum 0.2 cetearyl glucoside 4.0 cetyl alcohol 1.0 tristearin 0.8 acetyl glycol stearate 0.8 phenyl dimethicone 1.0 cyclopentasiloxane 4.0 tocopherol 0.7 copolymer sodium acrylate / dimethyl acryloyl laurate 0.5 isohexadecane 0.3 Polysorbate 80 0.8 glycolic ivy extract 2.0 theophylline 1.0 preservatives 0.8 perfumes 0.1 Demineralized water qs 100.00
Claims (8)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0411241A FR2876908B1 (en) | 2004-10-22 | 2004-10-22 | NEW USE OF CHAULMOOGRA OIL IN THERAPEUTICS AND COSMETICS. |
AT05812046T ATE451911T1 (en) | 2004-10-22 | 2005-10-21 | NOVEL USE OF CHAULMOOGRA OIL AND GUGGULIPIDS IN THERAPEUTICS AND COSMETICS |
EP05812046A EP1811953B1 (en) | 2004-10-22 | 2005-10-21 | Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics |
PCT/FR2005/002621 WO2006045932A2 (en) | 2004-10-22 | 2005-10-21 | Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics |
DE602005018384T DE602005018384D1 (en) | 2004-10-22 | 2005-10-21 | NOVEL USE OF CHAULMOOGRA OIL AND GUGGULIPIDES IN THERAPEUTICS AND COSMETICS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0411241A FR2876908B1 (en) | 2004-10-22 | 2004-10-22 | NEW USE OF CHAULMOOGRA OIL IN THERAPEUTICS AND COSMETICS. |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2876908A1 true FR2876908A1 (en) | 2006-04-28 |
FR2876908B1 FR2876908B1 (en) | 2007-01-19 |
Family
ID=34950748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0411241A Active FR2876908B1 (en) | 2004-10-22 | 2004-10-22 | NEW USE OF CHAULMOOGRA OIL IN THERAPEUTICS AND COSMETICS. |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2876908B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000055A1 (en) * | 2007-06-27 | 2008-12-31 | Natura Cosméticos S.A. | Process for preparing sapucainha oil or butter, cosmetic or pharmaceutical composition and use of the sapucainha oil or butter |
WO2011050433A1 (en) * | 2009-10-27 | 2011-05-05 | Natura Cosmeticos S.A. | Cosmetic composition comprising siliconed sapucainha ester |
WO2011080722A2 (en) | 2009-12-29 | 2011-07-07 | Natura Cosmeticos S.A | Use of skin permeation and retention enhancer compound in cosmetic and pharmaceutical compositions and cosmetic and pharmaceutical products containing said compound |
WO2012136930A2 (en) | 2011-04-05 | 2012-10-11 | Laboratoire Nuxe | Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2518402A1 (en) * | 1981-12-21 | 1983-06-24 | Sederma Sa | Cosmetic compsn. contg. chaulmoogra oil - used partic. for treating skin trouble, e.g. acne, and also in hair care and make up compsns. |
FR2706304A1 (en) * | 1993-06-15 | 1994-12-23 | Carita Sa | Use of Chaulmoogra oils in the cosmetic and pharmaceutical field, especially in dermatology, to harmonize the pigmentation of the skin. |
-
2004
- 2004-10-22 FR FR0411241A patent/FR2876908B1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2518402A1 (en) * | 1981-12-21 | 1983-06-24 | Sederma Sa | Cosmetic compsn. contg. chaulmoogra oil - used partic. for treating skin trouble, e.g. acne, and also in hair care and make up compsns. |
FR2706304A1 (en) * | 1993-06-15 | 1994-12-23 | Carita Sa | Use of Chaulmoogra oils in the cosmetic and pharmaceutical field, especially in dermatology, to harmonize the pigmentation of the skin. |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000055A1 (en) * | 2007-06-27 | 2008-12-31 | Natura Cosméticos S.A. | Process for preparing sapucainha oil or butter, cosmetic or pharmaceutical composition and use of the sapucainha oil or butter |
FR2918072A1 (en) * | 2007-06-27 | 2009-01-02 | Natura Cosmeticos Sa | PROCESS FOR THE PREPARATION OF SAPUCAINHA OIL OR BUTTER, COSMETIC OR PHARMACEUTICAL COMPOSITION AND USE OF SAPUCAINHA OIL OR BUTTER |
US9492372B2 (en) | 2007-06-27 | 2016-11-15 | Natura Cosmeticos S.A. | Process for preparing sapucainha oil or butter, cosmetic or pharmaceutical composition and use of the sapucainha oil or butter |
WO2011050433A1 (en) * | 2009-10-27 | 2011-05-05 | Natura Cosmeticos S.A. | Cosmetic composition comprising siliconed sapucainha ester |
WO2011080722A2 (en) | 2009-12-29 | 2011-07-07 | Natura Cosmeticos S.A | Use of skin permeation and retention enhancer compound in cosmetic and pharmaceutical compositions and cosmetic and pharmaceutical products containing said compound |
WO2012136930A2 (en) | 2011-04-05 | 2012-10-11 | Laboratoire Nuxe | Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation |
Also Published As
Publication number | Publication date |
---|---|
FR2876908B1 (en) | 2007-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1064931B1 (en) | Cosmetic composition containing at least one hydroxystilbene and ascorbic acid | |
EP1648569B1 (en) | Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite | |
FR2768927A1 (en) | USE OF ELLAGIC ACID, ITS SALTS, ITS METAL COMPLEXES, ITS MONO- OR POLYMERIC, MONO- OR POLYACYLATED DERIVATIVES IN THE FIELD OF COSMETICS AND PHARMACY, IN PARTICULAR DERMATOLOGY | |
WO2001095872A1 (en) | Cosmetic and/or dermatological composition based on cocoa extracts | |
FR2885050A1 (en) | Slimming cosmetic and/or pharmaceutical composition, useful for treatment of adipocytes of skin, comprises cocoa extract containing polyphenols | |
FR2907338A1 (en) | Use of ferulic acid, its salts and/or derivatives as lipolytic agent to prepare a cosmetic and/or pharmaceutical composition to prevent and/or treat the adipose overloads and/or cellulitis, by systemic and/or local administration | |
EP1811953B1 (en) | Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics | |
EP3684477B1 (en) | Cosmetic compositions for treating oily skins | |
EP1768684A1 (en) | Composition comprising a blue lotus extract having a relaxing effect on the skin | |
EP1448208B1 (en) | Composition based on diosgenin ester for topical use | |
FR2876908A1 (en) | Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis | |
EP2046356B1 (en) | Use of an extract of gleditsia in cosmetics and in dermatology | |
FR3005408A1 (en) | USE OF PETROSELINIC ACID TO COMBAT THE AESTHETIC DISORDERS OF SILHOUETTE ASSOCIATED WITH MODIFICATIONS OF ADIPOSE TISSUE | |
FR2876909A1 (en) | Cosmetic and/or pharmaceutical composition, to prevent or treat adipose overloads and cellulitis, comprises a combination of one or more xanthinic bases and chaulmoogra oil and/or its components | |
FR2876912A1 (en) | Use of guggulipids and/or Z-guggulsterone and E-guggulsterone to prepare a cosmetic or pharmaceutical composition for the treatment and prevention of fat accumulation and cellulitis | |
EP2811978B1 (en) | Use of an apple tree bark extract in a cosmetic anti-ageing composition | |
FR2974298A1 (en) | VEGETABLE EXTRACT COMPLEX FOR SKIN PROTECTION | |
FR3021539A1 (en) | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION COMPRISING A VEGETABLE EXTRACT AND A GENE ACTIVATOR | |
FR3099992A1 (en) | COSMETIC USE OF A SPECTABILE SEDUM EXTRACT AS A SLIMMING AGENT, AND COMPOSITIONS CONTAINING SUCH EXTRACT | |
FR2871382A1 (en) | Topical cosmetic/dermatological composition, useful to fight against the signs of aging, comprises a complex extract of blue lotus and poppy | |
CH689373A5 (en) | Cosmetic moisturising composition | |
EP2694028A2 (en) | Composition based on chaulmoogra oil and tribulus terrestris for skin pigmentation | |
EP2811977A2 (en) | Use of an apple tree leaf extract in a cosmetic skin-firming composition | |
FR2828400A1 (en) | Cosmetic composition useful for improving skin condition comprises insulin-like growth factor or its mimetic and a retinoid | |
FR2871381A1 (en) | Topical cosmetic/dermatological composition, useful e.g. to fight against signs of cutaneous ageing, comprises an marsh mallow extract (Althea officinalis) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TP | Transmission of property |
Owner name: SOCIETE DE RECHERCHE COSMETIQUE S.A.R.L., LU Effective date: 20140314 |
|
PLFP | Fee payment |
Year of fee payment: 12 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
CA | Change of address |
Effective date: 20170223 |
|
PLFP | Fee payment |
Year of fee payment: 14 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |
|
PLFP | Fee payment |
Year of fee payment: 17 |
|
PLFP | Fee payment |
Year of fee payment: 18 |
|
PLFP | Fee payment |
Year of fee payment: 19 |
|
PLFP | Fee payment |
Year of fee payment: 20 |